Technical analysis of Phio Pharmaceuticals Corp. (PHIO): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Price Performance
| 1 month | -4.85% |
| 3 months | -3.00% |
| Year-to-date | -4.85% |
| 1 year | -52.65% |
| 3 years | -92.65% |
| 5 years | -99.59% |
52-Week Range
| 52-week High | $4.19 |
| 52-week Low | $0.81 |
| Avg Volume (90d) | 476K |
Technical Indicators
| SMA 50 | $1.07 |
| SMA 200 | $1.12 |
| Beta | 0.81 |
| 30-day Volatility (annualised) | 46.8% |
| Price vs SMA 50 | -6.4% |
| Price vs SMA 200 | -10.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.05 | |
| 2025-11 | $1.26 | -38.5% |
| 2025-12 | $1.05 | -16.7% |
| 2026-01 | $1.01 | -3.8% |
| 2026-02 | $1.14 | +12.9% |
| 2026-03 | $1.22 | +7.0% |
| 2026-04 | $1.22 | +0.0% |
| 2026-05 | $1.11 | -9.0% |
| 2026-06 | $1.02 | -8.1% |
| 2026-07 | $1.02 | +0.0% |
| 2026-08 | $1.09 | +6.9% |
| 2026-09 | $1.00 | -8.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.00 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | 0.03 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 15.87 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.53 |